• Substance P (SKU B6620): Technical Guide for CNS & Inflammat

  2026-04-22

  Substance P (SKU B6620) is a high-purity tachykinin neuropeptide designed for research in pain transmission, neuroinflammation, and immune response modulation. This product offers strict solubility and stability characteristics critical for reproducible in vitro and ex vivo workflows. It is not intended for diagnostic or therapeutic use and should not be used outside validated research protocols.

• Fasudil (HA-1077) HCl: Applied ROCK Inhibition in Cancer and

  2026-04-22

  Fasudil (HA-1077) HCl stands out as a reliable, selective ROCK inhibitor for dissecting cell signaling, proliferation, and migration in cancer and hematological models. This article translates bench protocols and troubleshooting strategies into actionable guidance, bridging pathway insights and advanced workflow optimization for robust, reproducible results.

• A40926: Dalbavancin Precursor for Gram-Positive Research

  2026-04-21

  A40926 stands out as a premier dalbavancin precursor, enabling high-precision Gram-positive and Neisseria gonorrhoeae inhibition assays. This guide delivers workflow enhancements, troubleshooting insights, and evidence-driven protocol parameters to accelerate antibiotic discovery and resistance research.

• Verteporfin in Applied Research: Workflows for Photodynamic

  2026-04-21

  Verteporfin (CL 318952) stands out as a dual-action tool for photodynamic therapy and autophagy inhibition, unlocking robust workflows in ocular neovascularization and cellular senescence research. This article decodes protocol optimization, troubleshooting, and advanced use-cases for translational scientists leveraging Verteporfin from APExBIO.

• Protease Inhibitor Cocktail: MS-Compatible Protein Extractio

  2026-04-20

  APExBIO’s Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) redefines protein extraction workflows by delivering robust, broad-spectrum inhibition with mass spectrometry compatibility. Its AEBSF-free formulation ensures precise proteomics and biochemical assays, even in challenging cell and tissue contexts.

• Structural Determinants of ω-Agatoxin IVA Sensitivity in Cav

  2026-04-20

  This study presents high-resolution cryo-EM structures of the human Cav2.1 channel in complex with peptide toxins, revealing the molecular basis for the differential sensitivities of P-type and Q-type Cav2.1 channels to ω-agatoxin IVA. These insights advance mechanistic understanding and inform the design of subtype-selective calcium channel inhibitors relevant to neurophysiology and epilepsy research.

• NHS-Biotin for Precision Protein Labeling: Advanced Workflow

  2026-04-19

  NHS-Biotin transforms protein labeling and purification with its rapid, amine-specific reactivity and membrane-permeable properties. Recent innovations like peptidisc-assisted clustering now enable efficient engineering of multimeric protein assemblies, making APExBIO’s NHS-Biotin the go-to tool for next-generation biochemical research.

• Viral Targeting of RIPK3: Mechanisms Regulating Necroptosis

  2026-04-18

  This study identifies a class of viral proteins (vIRD) in orthopoxviruses that induce proteasome-mediated degradation of the necroptosis adaptor RIPK3, thereby modulating host inflammatory responses and viral pathogenesis. These findings clarify how viral evasion strategies intersect with the ubiquitin-proteasome system and highlight critical checkpoints for immune regulation.

• AO/PI Staining Solution: Precision in Fluorescent Cell Viabi

  2026-04-17

  AO/PI Staining Solution is a dual fluorescent DNA dye reagent enabling precise live/dead cell discrimination in cell counting assays. It outperforms traditional stains by leveraging membrane integrity and fluorescence criteria. This article details its mechanistic basis, benchmarked performance, and workflow integration for reproducible cell viability analysis.

• AZD3463: Potent ALK/IGF1R Inhibitor for Neuroblastoma Resear

  2026-04-16

  AZD3463 is a high-affinity, orally bioavailable ALK/IGF1R inhibitor used in neuroblastoma research. It blocks ALK-mediated PI3K/AKT/mTOR pathways and is effective against wild-type and mutant ALK, enhancing apoptosis and synergizing with chemotherapeutics.

• MG-132: Optimizing Proteasome Inhibition for Apoptosis Assay

  2026-04-15

  MG-132 (Z-LLL-al) enables highly selective, reproducible proteasome inhibition for apoptosis and cell cycle arrest studies, with robust performance in oxidative stress research. This article translates advanced findings and troubleshooting strategies into actionable protocols, highlighting APExBIO’s MG-132 as a benchmark for sensitive and reliable experimental workflows.

• Firefly Luciferase mRNA: Precision Assays with ARCA, 5mCTP,

  2026-04-14

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) delivers robust, low-immunogenicity gene expression reporting, enabling reliable quantitation in cell viability, gene expression, and in vivo imaging workflows. Its advanced chemical modifications and ARCA capping ensure consistent, high-sensitivity results even in challenging transfection scenarios.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Res

  2026-04-13

  Latrunculin A is a reversible inhibitor of actin assembly derived from marine sponges. It enables rapid and controlled actin cytoskeleton disruption for studies of cell morphology, motility, and viral pathogenesis. Robust evidence supports its use in dissecting actin–myosin II network function in vitro and in live-cell assays.

• Dehydroabietic Acid (SKU N2850): Reliable Dual PPAR-α/γ Tool

  2026-04-13

  This article provides an evidence-based exploration of Dehydroabietic acid (SKU N2850) as a dual PPAR-α/γ agonist for metabolic disorder research. Through scenario-driven Q&A, it addresses common laboratory challenges, protocol optimization, and vendor selection, emphasizing reproducibility and workflow compatibility for cell viability and lipid metabolism assays.

• Pazopanib (GW-786034): Precision RTK Inhibition in ATRX-Defi

  2026-04-12

  Explore how Pazopanib (GW-786034), a multi-targeted receptor tyrosine kinase inhibitor, is redefining translational cancer research. This thought-leadership article connects emerging mechanistic insights—especially in ATRX-deficient high-grade glioma—with actionable experimental strategies, competitive landscape analysis, and forward-looking guidance for researchers. Contextualized within APExBIO’s portfolio, the discussion transcends standard product pages by integrating cutting-edge evidence, protocol optimization, and strategic considerations for translational teams.

16189 records 1/1080 page Next 12345 下5页 Last page